![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Eli Lilly Asks FDA to Nix EUA for Bamlanivimab Alone
Eli Lilly Asks FDA to Nix EUA for Bamlanivimab Alone
![Eli lilly logo](https://www.fdanews.com/ext/resources/test/Drug-Images4/Lilly_Logo.jpg?t=1616695880&width=430)
Eli Lilly has asked the FDA to revoke the Emergency Use Authorization for its monoclonal antibody bamlanivimab as a monotherapy for COVID-19 patients, but said the request was not due to any new safety concerns.
Bamlanivimab in combination with another Lilly antibody, etesevimab, has proven to be a more effective treatment, including against variant strains of the SARS-CoV-2 virus that causes COVID-19 infections.
Eli Lilly and the U.S. government have reworked their supply deal to deliver bamlanivimab only in combination with etesevimab.
Upcoming Events
-
18Jul
-
21Oct